A Study of ACI-24 in Adults With Down Syndrome

Summary

This study is a prospective multicenter, placebo-controlled, double-blind, randomized study to assess the effect of one dose ACI-24 versus placebo over a 74-week treatment period and 26-week safety follow-up period.

Timeline

Start

2021-10

Primary completion

2024-04

Completion

2024-10

Outcome

Met primary endpoint

Stopped: “decision to proceed with an optimized study design and optimized vaccine formulation”

release “ACI-24, the predecessor of ACI-24.060, was safe and elicited an immune response in a Phase 1b clinical trial in adults with DS.” acimmune.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACI-24	Vaccine	—	—

Indications